All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit Know ALL.

  TRANSLATE

The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The ALL Hub
Brought to you by Scientific Education Support

The ALL Hub is an independent medical education platform, sponsored by Amgen and Autolus. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

View all

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

EBMT 2023

By Nan Lan

Share:

Featured:

Nan LanNan Lan

Apr 24, 2023

X post image

26 Apr 2023

CONGRESS|#EBMT23 Luxin Yang discusses long-term survival and toxicities of allo-HCT in patients with #ALL and previous CAR T-cell therapy. The cumulative incidence of EB and CMV reactivation were 78.7% and 74.6%. 3-year OS and PFS were 68.2% and 65.4% #ALLsm #medicalcongress

View on 

X post image

26 Apr 2023

CONGRESS|#EBMT23 Ayman Sayyed discusses the outcomes of allo-HCT in B-cell #ALL patients who received blinatumomab pre-transplant. Two-year OS, GRFS , TRM , and CIR in the blinatumomab group were 65.4%, 42.2%, 3.2% and 34.4%, respectively #ALLsm #medicalcongress

View on 

X post image

25 Apr 2023

CONGRESS|#EBMT23 Peter Bader @goetheuni presents analysis of patients with pB-ALL relapse after allo-HSCT who received CAR-T cell treatment with Tisa-cel. For CAR-T cell responders, the 2-year pRFS was 48.6% and the 2-year duration of B-cell aplasia was 45.0% #ALL #ALLsm

View on 

X post image

25 Apr 2023

CONGRESS|#EBMT23 @sghorashian @GreatOrmondSt presents data from a study investigating CART therapy for R/R B-ALL diagnosed in patients younger than 3 years. Response rates, long term outcomes and toxicity were similar to that in older children #ALL #ALLsm #medicalcongress

View on 

X post image

24 Apr 2023

CONGRESS|#EBMT23 Mohammad Vaezi presents analysis of the trends of allo-HCT outcomes in 1120 patients who underwent their first transplant. 5 year OS and 3 year relapse incidence improved over the 2 decades of follow up. There was no difference in NRM #ALL #ALLsm #medicalcongress

View on 

X post image

24 Apr 2023

CONGRESS|#EBMT23 @davidmarks1958 presents outcomes in patients with ND and R/R ALL who received Inotuzumab ozogamicin and proceeded to first allo-HSCT. Although the VOD/SOS mortality rate was higher, NRM at 12 months was lower #ALL #ALLsm #medicalcongress

View on 

X post image

24 Apr 2023

CONGRESS|#EBMT23 Bijal D. Shah presents subgroup analysis of the ZUMA-3 trial by prior therapies and subsequent alloSCT. Patients benefited from brexu-cel, with manageable safety, regardless of prior exposure to blinatumomab or alloSCT #ALL #ALLsm #medicalcongress

View on 

EBMT23

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

EBMT 2023European Society for Blood and Marrow Transplantation

Newsletter

Subscribe to get the best content delivered to your inbox